publication date: Aug. 6, 2020

NCI Trials

NCI Trials for August 2020

The National Cancer Institute approved the following clinical research studies last month.

For further information, contact the principal investigator listed.


Phase I – 10346

Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-Expressing Advanced Solid Tumors

National Cancer Institute LAO

O’Sullivan Coyne, Geraldine

(301) 402-9122


Phase I – 10367

A Phase 1b Study with Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML)

City of Hope Comprehensive Cancer Center LAO

Kelly, Kevin R.

(323) 865 3828 MTD


Phase I/II – 10366

A Phase 1/2 Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Davis, Sarah Lindsey

(303) 724-8681


Phase II – 10330

A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

Yale University Cancer Center LAO

Ingham, Matthew

(202) 285-4944


Phase II – 10334

BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2 (BLAST MRD AML-2): A Randomized Phase 2 Study of the Venetoclax, Azacitadine, and Pembrolizumab (VAP) Versus Venetoclax and Azacitadine as First Line Therapy in Older Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible or Who Refuse Intensive Chemotherapy

Yale University Cancer Center LAO

Zeidan, Amer M.

(203) 737-2572


Phase II – A091902

A Multicenter Phase II Trial of Paclitaxel with and Without Nivolumab in Taxane NaÔve, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma

Alliance for Clinical Trials in Oncology

Grilley-Olson, Juneko E.

(919) 843-5497


Phase II – AREN1921

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Children’s Oncology Group

Geller, James Ian

(513) 636-6312 X 6312


Phase II – EA6192

A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)

ECOG-ACRIN Cancer Research Group

Gibney, Geoffrey Thomas

(202) 444-2223


Phase II – EA8185

Phase 2 Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage 3, Node PosItive BladdeR CancEr (INSPIRE)

ECOG-ACRIN Cancer Research Group

Joshi, Monika

(717) 798-8678


Phase II/III – NRG-HN006

Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer

NRG Oncology

Lai, Stephen Yenzen

(713) 792-6528


Phase III – A031902

CASPAR – A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer

Alliance for Clinical Trials in Oncology

Rao, Arpit

(612) 625-9604

Copyright (c) 2020 The Cancer Letter Inc.